Scott Myers, Chairman and Chief Executive Officer
Scott Myers has served as our President and Chairman and Chief Executive Officer since June 2018 and September 2018 respectively. Prior to joining Rainier Therapeutics Scott Myers has more than 20 years of biopharmaceutical industry experience in product development, commercialization and corporate transactions. He was most recently CEO, President and a Director of Seattle-based Cascadian Therapeutics (CASC), an oncology company, until it was acquired by Seattle Genetics in March of 2018. Prior to Cascadian, he was CEO of Aerocrine AB (AERO), a medical device company based in Stockholm, Sweden, and Morrisville, NC, until it was acquired by Circassia, PLC in 2015. Prior to Aerocrine, Scott held senior commercial operations, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson & Johnson. From 2012-2014, Scott was an independent director of Orexo, AB (OREX), a Swedish CNS company. Currently, Scott is an Independent Director and member of the Audit Committee for Harpoon Therapeutics (HARP), a publicly traded Oncology Company focusing on innovative T Cell engaging platforms. Scott is also an Independent Director and member of the Nomination and Governance committee of SelectaBio (SELB), SelectaBio has developed the ImmTOR platform focused on the treatment of Gout and other novel therapies for immune system diseases. Scott earned his BA in biology from Northwestern University and his MBA from The University of Chicago Booth School of Business.
Julie Eastland, Chief Financial Officer and Chief Business Officer
Julie Eastland most recently served as Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, from September 2010 to May 2018, having helped negotiate the sale of the company to Seattle Genetics and then assisted in the subsequent transition. From 2006 to 2010, she was the Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company. Prior to VLST, Julie held various financial and strategic management positions at publicly-traded biotechnology companies including Dendreon and Amgen. She is a Director and Audit Committee Chair at Harpoon Therapeutics, an immune-oncology company publicly traded on Nasdaq and a Director of Pascal Biosciences, an oncology company publicly traded on the Toronto Venture Exchange. She received an MBA from Edinburgh University Management School and a BS in finance from Colorado State University.
Steve Abella, MD, Advisor to Management Team
Esteban (Steve) Abella has been actively involved in cancer clinical trials research for 30+ years including over 10 years in pharmaceutical industry, most recently serving as CMO at Rainier Therapeutics since 2017. Steve previously was a Senior Director leading the Zydelig Non-Hodgkin’s lymphoma and leukemia efforts, program lead for entospletinib and Ambisone, as well as serving as a core member of the oncology senior leadership team. Prior to that he served as Executive Director at Amgen predominately responsible for the white cell franchise (Neulasta/Neupogen) global development efforts across clinical research and medical affairs. His clinical experiences over the 23 years prior joining industry, span 15 years in academic oncology, serving as a Professor of Pediatric, Oncology, and Medicine at the Barbara Ann Karmanos Cancer institute predominately focused in stem cell transplantation and oncology clinical trials. Subsequently, he focused on developing and serving as the initial group president for a large multispecialty private practice group in Arizona of over 60 physicians. Steve completed his fellowship and residency training at Wayne State University School of Medicine after graduating with a degree in medicine from the Universidad Central del Este. He attended the University of Pennsylvania for undergraduate studies.
Valerie Fauvelle, Vice President, Advisor to Management Team
Valerie Fauvelle has more than 19 years of Regulatory Affairs experience in drug development. Prior to BioClin Therapeutics, Ms. Fauvelle worked at Cascadian Therapeutics, most recently as Senior Director, Regulatory Affairs, with primary responsibility for INDs and international submissions for treatments of multiple cancers. During her 8 years with Cascadian Therapeutics, she played a key role in the strategic development of the pivotal program for HER2+ breast cancer. Prior to Cascadian Therapeutics, she held positions with Gilead Sciences, ICOS, and Seattle Genetics, working on both biologics and small molecules targeting cancer, urology, respiratory and cardiovascular indications. She holds a BA in psychology from the University of Washington and a MSc in Health Sciences from The George Washington University School of Medicine. In addition, she has a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society.